Denali Therapeutics Inc.
NASDAQ:DNLIBiotechnology
Healthcare
$18.20 +0.40%
+$0.09 today
- Market cap
- $2.92B
- Beta
- 1.01
- P/E (TTM)
- -8.7
- EPS (TTM)
- -$2.72
52W Low $12.58High $24.65
Volume 1.27M
Average 1.84M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$412.60M
FY 2025 · Annual
Investing Cash Flow
$255.28M
FY 2025 · Annual
Financing Cash Flow
$189.22M
FY 2025 · Annual
-60.9% YoYCash Flow Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (290.58M) | (325.99M) | (145.22M) | (422.77M) | (512.54M) |
| Depreciation & Amortization | 8.59M | 10.38M | 16.73M | 8.99M | 14.81M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 85.25M | 99.85M | 108.1M | 102.88M | 99.63M |
| Change in Working Capital | (20.41M) | (24.03M) | (289.93M) | 16.94M | 149K |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 3.71M | 2.27M | 2.43M | 1.44M | (7.52M) |
| Other Working Capital | (24.12M) | (26.3M) | (292.36M) | 15.5M | 7.67M |
| Other Non-Cash Items | 5.76M | (4.93M) | (47.67M) | (53.73M) | (14.65M) |
| Operating Cash Flow | (211.39M) | (244.72M) | (357.99M) | (347.69M) | (412.6M) |
| Capital Expenditures | (8.5M) | (17.83M) | (12.94M) | (15.91M) | (9.5M) |
| Acquisitions (Net) | 0 | 123.55M | 0 | 0 | 0 |
| Purchases of Investments | (1.42B) | (1.12B) | (1.81B) | (1.23B) | (441.26M) |
| Sales of Investments | 1.41B | 991.49M | 2.08B | 1.16B | 706.05M |
| Other Investing Activities | 0 | (123.55M) | 0 | 0 | 0 |
| Investing Cash Flow | (21.63M) | (141.39M) | 249.31M | (88.76M) | 255.28M |
| Debt Repayment | 0 | 0 | 0 | (32.34M) | (8.17M) |
| Common Stock Issued | 19.35M | 296.22M | 17.82M | 499.25M | 197.38M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 14.46M | 0 | 17.39M | 0 |
| Financing Cash Flow | 19.35M | 310.67M | 17.82M | 484.3M | 189.22M |
| Effect of Forex Changes | 0 | 0 | (75K) | 0 | 0 |
| Net Change in Cash | (213.67M) | (75.43M) | (90.94M) | 47.85M | 31.9M |
| Free Cash Flow | (219.89M) | (262.55M) | (370.93M) | (363.61M) | (422.1M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$512.5M
+ D&A$14.8M
+ Stock-Based Comp$99.6M
+ Deferred Tax$0
+ Working Capital$149.0K
- Other Non-Cash-$14.7M
= Operating Cash Flow-$412.6M
- Capex-$9.5M
= Free Cash Flow-$422.1M
Analysis
FY2025 free cash flow is -$422.1M. FCF conversion is 82.4% of net income. Operating cash flow was -$412.6M, with capex of -$9.5M. The largest bridge item is Stock-Based Comp at $99.6M.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 8-K | Current report | Nov 3, 2026 | |
| 10-Q | Quarterly report | Nov 3, 2026 | |
| 4 | Statement of changes in beneficial ownership | Sep 9, 2026 | |
| 4 | Statement of changes in beneficial ownership | Sep 4, 2026 | |
| 4 | Statement of changes in beneficial ownership | Sep 3, 2026 |
Does DNLI generate free cash flow?
Denali Therapeutics Inc. (DNLI) generated -$422.10M of free cash flow in fiscal 2025.
How much operating cash flow does DNLI produce?
Operating cash flow was -$412.60M, before capital expenditures of $9.50M.
Continue the stock analysis
Jump to another research area for this company.